Devices guided by the Acclarent Navigation Technology have described risks including the potential for unintended injury to the orbits or CNS as a consequence of inaccurate navigation. Am I missing something? Acclarent (a subsidiary of Johnson & Johnson) has developed TruDi™, a real-time, three-dimensional navigation system for Ear Nose & Throat procedures performed in the operating room and in the ENT office. Like post, Posted 2 years ago TruDi leverages Biosense Webster’s advanced imaging system which utilizes electromagnetic technologies to help electrophysiologists navigate the beating heart by generating an accurate map, and pinpoints the exact location and orientation of catheters used during diagnostic and therapeutic procedures. #Innovation #SpineSurgery pic.twitter.com/c4B3…, #HeartValveWeek19 is in full swing!

Frankly, it’s likely only a matter of time before J&J realizes its mistake in both launching this flawed equipment as well as its acquisition of Acclarent in general. “TruDi enables precise localization of the surgical device relative to the preoperative CT scan, facilitating the surgeon’s understanding of the complex anatomy of the narrow spaces of the paranasal sinuses,” said Acclarent consultant Dr. Martin J. Citardi, Professor and Chair of the Department Otorhinolaryngology-Head and Neck Surgery at McGovern Medical School at The University of Texas Health Science Center at Houston. Mini Spieluhr Elefant . Medtechy’s overall goal is to help the medical sales industry make more informed decisions when changing jobs and also keep employers and recruiters honest, Take 30 seconds and let us know your current deal.*. The product information included here may not be appropriate for use outside the United States, and the information from other sites you visit may not be appropriate for use in the United States. Fast Anatomical Mapping (FAM): FAM is a real-time imaging tool that documents surgical changes to the anatomy. ENT's are not like EP's and TruDi doesn't make sense for ENT surgeons. Advaxis Has Several Catalysts in Early 2020, Starting With Data to Be Presented at Upcoming Meetings, All Signs Pointing to FDA Approval for Agile Therapeutics’ Twirla, KISS (Keep it Simple Stupid): Why I’m Heavily Invested in Amarin, Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre. It is intended for visitors from the United States. bit.ly/2KICViN #WeAreStryker pic.twitter.com/rFE1…, ⚡Can you solve this case?⚡Patient: an 84-year-old woman woke up with left sided weakness. No shavers, nothing but balloon monkeying around to nav a balloon. Recently, Acclarent let go of all their clinical support personnel literally right before launching the TruDi....the Acclarent sale team has no experience selling or supporting sophisticated capital equipment and now no infrastructure to successfully support post sale like Medtronic, Stryker and BrainLab.